Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Biosimilar market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.3% during the forecast period.
This report presents the market size and development trends by detailing the Biosimilar market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Biosimilar market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Biosimilar industry and will help you to build a panoramic view of the industrial development.
Biosimilar Market, By Type:
Human Growth Hormones
Monoclonal Antibodies
Insulin
Peptides
Erythropoietin
Others
Biosimilar Market, By Application:
Oncology
Chronic and Autoimmune Diseases
Growth Hormone Deficiency
Infectious Diseases
Others
Some of the leading players are as follows:
BIOCAD
Allergan plc
Pfizer
Intas Pharmaceuticals Limited
Novartis
Celltrion
BioXpress Therapeutics
Genor BioPharma
Dr. Reddy’s Laboratories
Biocon
Reliance Life Sciences
Boehringer Ingelheim
Coherus BioSciences
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Biosimilar Market: Technology Type Analysis
-
4.1 Biosimilar Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Biosimilar Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Human Growth Hormones
4.3.2 Monoclonal Antibodies
4.3.3 Insulin
4.3.4 Peptides
4.3.5 Erythropoietin
4.3.6 Others
5 Biosimilar Market: Product Analysis
-
5.1 Biosimilar Product Market Share Analysis, 2018 & 2026
-
5.2 Biosimilar Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Biosimilar Market: Application Analysis
-
6.1 Biosimilar Application Market Share Analysis, 2018 & 2026
-
6.2 Biosimilar Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Oncology
6.3.2 Chronic and Autoimmune Diseases
6.3.3 Growth Hormone Deficiency
6.3.4 Infectious Diseases
6.3.5 Others
7 Biosimilar Market: Regional Analysis
-
7.1 Biosimilar Regional Market Share Analysis, 2018 & 2026
-
7.2 Biosimilar Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 BIOCAD
9.1.1 BIOCAD Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Allergan plc
9.2.1 Allergan plc Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Pfizer
9.3.1 Pfizer Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Intas Pharmaceuticals Limited
9.4.1 Intas Pharmaceuticals Limited Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Novartis
9.5.1 Novartis Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Celltrion
9.6.1 Celltrion Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 BioXpress Therapeutics
9.7.1 BioXpress Therapeutics Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Genor BioPharma
9.8.1 Genor BioPharma Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Dr. Reddy’s Laboratories
9.9.1 Dr. Reddy’s Laboratories Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Biocon
9.10.1 Biocon Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Reliance Life Sciences
9.11.1 Reliance Life Sciences Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 Boehringer Ingelheim
9.12.1 Boehringer Ingelheim Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 Coherus BioSciences
9.13.1 Coherus BioSciences Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
The List of Tables and Figures (Totals 110 Figures and 136 Tables)
Figure Human Growth Hormones Biosimilar market, 2015 - 2026 (USD Million)
Figure Monoclonal Antibodies Biosimilar market, 2015 - 2026 (USD Million)
Figure Insulin Biosimilar market, 2015 - 2026 (USD Million)
Figure Peptides Biosimilar market, 2015 - 2026 (USD Million)
Figure Erythropoietin Biosimilar market, 2015 - 2026 (USD Million)
Figure Others Biosimilar market, 2015 - 2026 (USD Million)
Figure Oncology market, 2015 - 2026 (USD Million)
Figure Chronic and Autoimmune Diseases market, 2015 - 2026 (USD Million)
Figure Growth Hormone Deficiency market, 2015 - 2026 (USD Million)
Figure Infectious Diseases market, 2015 - 2026 (USD Million)
Figure Others market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Biosimilar market, by country, 2015 - 2026 (USD Million)
-
Table North America Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table North America Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table North America Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table Canada Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table Canada Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Europe Biosimilar market, by country, 2015 - 2026 (USD Million)
-
Table Europe Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table Europe Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table Europe Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table Germany Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table Germany Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table France Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table France Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table Italy Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table Italy Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table Spain Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table Spain Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Biosimilar market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table China Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table China Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table Japan Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table Japan Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table India Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table India Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Biosimilar market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table MEA Biosimilar market, by country, 2015 - 2026 (USD Million)
-
Table MEA Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table MEA Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table MEA Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Biosimilar market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Biosimilar market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Biosimilar market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table BIOCAD Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Allergan plc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Intas Pharmaceuticals Limited Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novartis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Celltrion Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table BioXpress Therapeutics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Genor BioPharma Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Dr. Reddy’s Laboratories Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Biocon Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Reliance Life Sciences Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Coherus BioSciences Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
